Current Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend iPTH target levels of 2-9 times the upper limit of normal for the assay, reflecting the increased risk with both low (adynamic bone disease) and high (high bone turnover disease) PTH levels (1). Here, PTH is linked to kidney disorder.